MOESM1 of A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy

Additional file 1: Table S1. The primer sequences for GAPDH, Bcl-2, Bax, Caspase-3, PARP, PTEN and p53. Figure S1. 1H NMR spectra of (A) CS in D2O, (B) CS-RAFT in DMSO-d6 and (C) CS-co-PNVCL1 in DMSO-d6. Figure S2. Size distributions of NPs formed from (A) CS, (B) CS-co-PNVCL, (C) CPP-CS-co-PNVCL1, and (D) CPP-CS-co-PNVCL1@DOX NPs. (E) The particle size of the CPP-CS-co-PNVCL1@DOX NPs during storage for 7 days. Values are given as mean ± S.D (n = 3). Figure S3. MMP-2 protein expression levels in HUVEC and MCF-7 cells. **P < 0.01. Data are given as mean ± S.D (n = 3). Figure S4. IC50 values against MCF-7 cells for the different formulations (n = 6; results are shown as mean ± S.D, *P < 0.05, **P < 0.01 compared to free DOX). Figure S5. Hemocompatibility and pharmacokinetics. (A) Hemolytic activity of free DOX, CPP-CS-co-PNVCL1 and CPP-CS-co-PNVCL1@DOX NPs on rat red blood cells (n = 3, mean ± S.D). (B) Plasma concentration versus time curves for free DOX and CPP-CS-co-PNVCL1@DOX NPs in SD rats (n = 3, mean ± S.D). Figure S6. Representative images of tumors in MCF-7 xenograft nude mice after treatment for 30 days. The arrows indicate the tumor foci. Figure S7. mRNA expression levels for Bcl-2, Bax, Caspase-3, PARP, PTEN, and p53 in the tumor tissues of MCF-7 tumor-bearing mice after treatment for 30 days. n = 6, results shown as mean ± S.D; *P < 0.05, **P < 0.01 as compared to the saline group.